Alaunos Therapeutics Inc (TCRT)

[dirtydozen911]

it closed the day at $3.40...right on the line of lin /reg50.....big vol,but I expect this to dive some more tomorrow......their "sleeping beauty platform" was hot for a couple years, but another company under the XON umbrella had a better car-t program...….been quiet this last year, however, you don`t get in to M D Anderson, without something under the hood....if they remain quiet, this could slide under $2 again.....this one is a tough call....good luck if you jump in !....I`m gonna watch the dilution for a week and then think about it again....with wrnts and offering....O S could easily be 225 mill or so...….too high for a small bio without revenue..gl

[ClayTrader]

* * $ZIOP Video Chart 02-05-2020 * *

Link to Video - click here to watch the technical chart video

[eddyimano]

They are trading already. How is it IPO now? I need to be educated.

[dirtydozen911]

been trading this for years......havn`t been in it for quite a while......stuck in the 4-5 $ channel.....this new offering puts them well over 200mill O S...….they need to come out with some "killer news" from M D Anderson......otherwise this will head back down towards a buck.....$1.50 low about a year ago.....I see big R/S in march....CAUTION!!!...glta

[jondoeuk]

We know about the product, they are going to target more neoantigens, working on 'next gen' versions (likely multiplex editing) [1], addressing manufacturing and should have dosed the first patient. If you have info on all this when it comes to ZIOP then do share it.

Ref:
1 (data from CRSP) https://crisprtx.gcs-web.com/static-files/8ea0746a-7aaf-4350-a451-db66efa26f6b

[jondoeuk]

I think a better video is Demystifying Medicine. At around the 53 minute mark Dr. Rosenberg says the reason why vaccines have failed is because they don't generate enough T-cells to impact the cancer and you can't get rid of enough Tregs, MDSCs and M2 macrophages. Also, (in my view) he forgot about targets [1].

To address the first problem GRTS is using a heterologous prime-boost vaccine. Preclinical data show this not only induces a T-cell response which is comparable to different adoptive cell transfer treatments, but also the cells persist longer [2]. The early human data (more will likely be presented at AACR and ASCO) are pretty encouraging [3].

The second can be dealt with via mAbs and/or small molecules (that deplete and/or reprogramme) which are in development.

As for the third the company tested its selection platform (which they continue to improve) against public methods and looked at how both compared to the tandem minigene approach used by Dr. Rosenberg/US NCI [4]. For the top twenty MHC Class I restricted neoantigens we know the majority (19/26, 73%) would be included vs. only 9/26 (35%) with public tools. Sometime this year they plan to incorporate MHC Class II restricted neoantigens in their vaccines as the dataset and model for these targets will be sufficiently robust. This should improve the efficacy [5] and will try to prioritise clonal neoantigens [6].

In addition, they have a deal with BLUE [7].

Refs:
1 https://videocast.nih.gov/summary.asp?Live=30267&bhcp=1
2 https://cancerres.aacrjournals.org/content/78/13_Supplement/724
3 https://www.fiercebiotech.com/biotech/gritstone-posts-one-most-potent-immunogenic-responses-for-a-neoantigen-vaccine
4 https://www.nature.com/articles/nbt.4313
5 https://www.nature.com/articles/s41586-019-1671-8
6 https://science.sciencemag.org/content/351/6280/1463
7 https://www.businesswire.com/news/home/20180823005039/en/bluebird-bio-Gritstone-Oncology-Announce-Strategic-Collaboration

[jondoeuk]

I'm not giving any advice nor do I have a (short) position in this company and don't plan to initiate one anytime soon.

[DennyCrane550]

So your view is short ZIOP
Buy Gritstone, Gilead, Sangamo

Ok, got it

[DennyCrane550]

Ok, got it!
u think PACT pharma is ahead, cool

[DennyCrane550]

Watch this in full
Rosenberg addresses Cancer Vaccines during Q&A

Then later while he is in the audience... Rosenberg questions Nishimura + Panel

https://videocast.nih.gov/summary.asp?live=29065&bhcp=1

[jondoeuk]

He said they had to make some amendments to the IND and by now should have dosed the first patient. With the money they will open a GMP manufacturing facility in South San Francisco sometime this year to support the end-to-end production, supply chain and leverage the in-house manufacturing facility to automate manufacturing and analytical processes to reduce cycle time and manufacturing cost.

[jondoeuk]

This is very likely GILD's (under CRADA) https://clinicaltrials.gov/ct2/show/NCT03412877

Last year SGMO got an upfront payment of $150M from GILD and are eligible to receive up to $3.01B in potential milestones. They are working together on a program that creates both viral and non-viral methods to disrupt and insert certain genes into T and NK cells (both autologous and allogeneic (from healthy donors and induced pluripotent stem cells)), including the insertion of genes that encode CARs, TCRs and NKRs directed to up to ten mutually agreed targets. GILD is responsible for all clinical development costs and the commercialisation of any resulting approved product(s).

The first allogeneic product (from healthy donors) is an anti-CD19 CAR-T and a PhI trial should be open in 2H. The second is another allogeneic (again, from healthy donors) CAR-T targeting CD-19/20 (using a bicistronic vector, which allows for the expression of two different CARs on the same cell). It will use Hu19 [1], but I don't know when a PhI is going to start. A third product (unknown) is now moving forward. Based on this I would be surprised if a fourth wasn't in the works.

Once the neoantigen reactive TCR-T trial has more data they could move forward with others as GILD have their own method to screen patient TCRs for reactivity [2] and therefore don't need to rely on a tandem minigene library used by Dr. Rosenberg/US NCI. However, patients could lack T-cells with an adequate affinity due to TCR and other editing. To overcome such limitations, tumour-specific TCRs harvested from healthy donors could be used instead (they are likely working on this) [3].

Also, with synNotch T (and NK) cells can be engineered to locally produce a range of payloads, including pro-inflammatory cytokines and checkpoint antibodies. Given the flexibility of this, it should be possible for the cells to produce many, 'customised' for different cancer types. Some might act in concert with T or NK cell killing and others might act independently to remodel the immunosuppressive TME and engage the host immune system. Significantly, localised production should avoid the toxicities observed with systemic delivery and reduce costs [4].

In addition, the (CAR)NK cells could be used in patients whose cancer has become resistant to T-cell [5-7]. Data from another group shows activity [8].

Refs:
1 https://ashpublications.org/blood/article/132/Supplement%201/697/266071/Low-Levels-of-Neurologic-Toxicity-with-Retained
2 https://www.nature.com/articles/nm.3359
3 https://science.sciencemag.org/content/352/6291/1337
4 https://www.cell.com/fulltext/S0092-8674(16)31244-2
5 https://www.cell.com/cell/fulltext/S0092-8674(17)30065-X
6 https://www.sciencedirect.com/science/article/pii/S2211124719310502
7 http://jem.rupress.org/content/209/13/2351.long
8 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(19)30097-8

[DennyCrane550]

full vid https://t.co/ghIGTZCNXR

[jondoeuk]

''1)
In the Nov 26th 2019 PACT Pharma video -
President/Chief Tech Tim Moore says they will go after 1 Neoantigen and potentially as much as THREE.... you can suggest they are doing 4 and wayyy ahead if you want... But that's simply NOT THE CASE''

In the current trial, they are targeting a single neoantigen [1], but we know from the PR they will target more. This stated four [2] and I've heard more (sources I trust).

''2)
ZIOP has a Phase 2 - you try to dismiss/downgrade that all u want.''

Again, I know this. The estimated primary completion date is Dec 31, 2028 [3].

''3)
PACT Pharma has not DOSED as of Nov 26th per Tim Moore... in fact They have had to amend their IND several times.
You act like they are way ahead and yet they too have not DOSED... their Phase 1.''

Care to cite this video and the time at which Mr. Moore stated this?

''You would do well to look up Dr Rosenberg opinion of Neon/Gritstone and his discussion with Dr Michael Nishimura''

What does he say in them?

''Good luck catching $ZIOP with your Cancer Vaccines''

ZIOP's IL-12 has failed in melanoma, breast and has yet to show any activity in rGBM. We also know that they have been 'leapfrogged' in the CAR-T space and when it comes to vaccines GRTS have presented some early data on their vaccine [4].

Refs:
1 https://clinicaltrials.gov/ct2/show/NCT03970382
2 https://www.biocentury.com/bc-extra/preclinical-news/2019-07-22/pact-makes-case-neoantigen-specific-tcrs-patient-blood
3 https://clinicaltrials.gov/ct2/show/NCT04102436
4 https://www.fiercebiotech.com/biotech/gritstone-posts-one-most-potent-immunogenic-responses-for-a-neoantigen-vaccine

[DennyCrane550]

Additionally ~

You do of course realize who led that round of investment into PACT Pharma?....

Wonder why/how they came to the conclusion that TCR Neoantigen Non Viral Personalized - is a great path forward/worth the big bet.... hmmmm,

[DennyCrane550]

You have a few things wrong here, CLSM/JoeDoeUk

1)
In the Nov 26th 2019 PACT Pharma video -
President/Chief Tech Tim Moore says they will go after 1 Neoantigen and potentially as much as THREE.... you can suggest they are doing 4 and wayyy ahead if you want... But that's simply NOT THE CASE

2)
ZIOP has a Phase 2 - you try to dismiss/downgrade that all u want.

3)
PACT Pharma has not DOSED as of Nov 26th per Tim Moore... in fact They have had to amend their IND several times.
You act like they are way ahead and yet they too have not DOSED... their Phase 1.


Spread your fear, uncertainty, doubt at $IOVA (no clue what you have against $ZIOP)... and Cheerleader your Gritstone/Neon Cancer Vaccines elsewhere.

You would do well to look up Dr Rosenberg opinion of Neon/Gritstone and his discussion with Dr Michael Nishimura

Good luck catching $ZIOP with your Cancer Vaccines

[jondoeuk]

Well, nothing has been confirmed by the company (a PhI at MD Anderson) and the NCI trial still hasn't started. Meanwhile, others, such as PACT Pharma are not waiting around https://www.prnewswire.com/news-releases/pact-pharma-raises-75m-in-oversubscribed-series-c-financing-to-develop-fully-personalized-neotcr-t-cell-therapies-for-patients-with-cancer-300985029.html

They (PACT) have their own methods of identifying neoantigen-specific T-cells in the blood [1] and use a nonviral (an undisclosed, CRISPR-based approach) which has been translated into a single-step (c)GMP manufacturing process.

The product consist mainly of T-cells of the ''younger'' Tscm [2,3] and Tcm [4] phenotype and are polyfunctional [5]. Also, it contains CD4+ in addition to CD8+ T-cells and we know the former are critical for durable responses [6,7].

Sometime this year they will move to a product that has up to at least four TCRs, their HLA catalog enables analysis for over 99% of the population and clonal neoantigens are prioritised [8].

Refs:
1 https://www.cell.com/cell-reports/fulltext/S2211-1247(19)31022-8
2 https://www.nature.com/articles/nm.4241
3 https://www.nature.com/articles/nm.2446
4 https://www.pnas.org/content/102/27/9571.long
5 https://cancerres.aacrjournals.org/content/79/13_Supplement/1433
6 https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201343718
7 https://www.jimmunol.org/content/174/5/2591
8 https://science.sciencemag.org/content/351/6280/1463.long

[WalkingHome]

"engineering" Yes Science is meets technology.
The inflection point is upon us.
Some of the new hires appear to be about implementation, technology and scaling operations. There is a key player in operations at Eden as i recall.
very excited.

[DennyCrane550]

Yep Biotech daily moves are bananas

This is heavily shorted, misunderstood... terrific potential... there are several key hires that few are paying attention too.

A few breaks go ~> Ziopharm's way + => the stock will rocket.

The economy could go any direction but Ziopharm is getting very close to some BIG news... we shall see... need execution from Rosenberg, Deniger, Cooper, Spencer, + UT MD Anderson.
I think its working like a swiss watch precision... its more of an engineering problem now, versus whether some molecule works or not.

[WalkingHome]

Yes good to be on the same team with you. Lots of dynamics here.
Great Science Team
Expanding top notch management team
Building out staff to scale the science to operations
Deep ties with MD Anderson Oncology, Science, facilities, data, and patients
New CFO brought in with expertise in bio mergers & acquisitions
experience with the dealing with the Hedge funds, investors, etc..

This is a longer play for me. not a day trade. I cannot compete with day traders, i can go with Value

[DennyCrane550]

It's not just China... for Eden/Triarm Bio.... I have identified Taiwan Docs that ZIOP is using/working with, etc.

Top Notch.

WalkingHome, as you will recall from my other investments.... i dig deep... i talk with all stacks of the poker table... large holders, retail, shorts, etc. I never stop digging

[WalkingHome]

lots of potential here. the question long term is how far can this go.
The China Play with Eden Cell, is never mentioned. The potential here is Awesome. In country partner in China, with great staff, Scaling up for centralized cost effective treatment in China. Us will be different.

the question in the US is will ZIOP bring this to market on their own or partne, merge with a big pharma

[DennyCrane550]

"If the trial does happen"

so you dont think Houston TCR trials will happen... off chance it happens, u see only Phase 1...... ok, I got it, James Peters/CLSM/JonDoe

[jondoeuk]

''Be Negative Nancy if you want....

Rosenberg said he is speeding up enrollment to 1 patient per cohort / every 3 weeks in the other Viral TCR NeoAntigen Trial per video April 2019.''

A few days around the estimated start date was the 9th and now it has been changed to the 11th. But this has been the case for the last few months (since Sept).

''While you wait to the year 2028

Dr Drew Deniger + Ziopharm is staffing up with Ana Beatriz Korngold, Tom Spencer, + others in Houston... to launch ZIOP's own controlled TCR NeoAntigen Trial... do you think it will be Phase 1?... or Phase 2/3? and will it be as slow as Govt Longitudinal study?... if they start showing efficacy... game set match - Jon Doe Uk, innit?''

Knowing this company I wouldn't expect much. If the trial does happen, I will likely be a PhI and should move slightly faster (once open and enrolling) than the one at the NCI. Also, being an open label (I assume) they can report data when they see fit.

[jondoeuk]

Wow, more mice data!

[whytestocks]

News: $ZIOP Ziopharm Oncology Presents Pre-Clinical Data Validating "Rapid Personalized Manufacture" (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc....

In case you are interested ZIOP - Ziopharm Oncology Presents Pre-Clinical Data Validating "Rapid Personalized Manufacture" (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

[Tempy]

We could see new 52 week high going into the end of the year...

[whytestocks]

News: $ZIOP Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined with full dose of a PD-1 inhibitor; favorab...

Read the whole news ZIOP - Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

[ClayTrader]

* * $ZIOP Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

[WalkingHome]

Non-Viral TCR Gene Therapy
updates

https://clinicaltrials.gov/ct2/history/NCT04102436?A=1&B=3&C=Side-by-Side#StudyPageTop

[DennyCrane550]

https://twitter.com/DennyCrane550/status/1177066311366696962?s=19

[WalkingHome]

"2. Results may be observable on a per patient basis quickly - weeks."

A Phase II Study Using Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer - http://ClinicalTrials.gov. Starts in 5 days
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping...
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in...
clinicaltrials.gov
9:44 AM · Sep 25, 2019·Twitter for iPhone
6
Retweets
20
Likes
ThomasUBarton
@ThomasUBarton1
·
7h
Replying to
@ThomasUBarton1
2. Results may be observable on a per patient basis quickly - weeks.
https://twitter.com/ThomasUBarton1/status/1176854964448006150

[DennyCrane550]

Be Negative Nancy if you want....

Rosenberg said he is speeding up enrollment to 1 patient per cohort / every 3 weeks in the other Viral TCR NeoAntigen Trial per video April 2019.

While you wait to the year 2028

Dr Drew Deniger + Ziopharm is staffing up with Ana Beatriz Korngold, Tom Spencer, + others in Houston... to launch ZIOP's own controlled TCR NeoAntigen Trial... do you think it will be Phase 1?... or Phase 2/3? and will it be as slow as Govt Longitudinal study?... if they start showing efficacy... game set match - Jon Doe Uk, innit?

[jondoeuk]

So 2-4 years to complete enrolment and estimated primary completion date is 2028. Based on that I wouldn't expect to see data anytime 'soon.' Also, SB is being used [1] and we know from other data acquired resistance is going to be a problem [2]. In addition, nothing has been discussed about ways to try and improve the depth and duration in patients that do respond.

Refs:
1 https://postimg.cc/hQg9nqXX
2 https://cancerimmunolres.aacrjournals.org/content/7/4/534.long

[DennyCrane550]

Time is NOW to buy $ZIOP -- Dont MISS The Train

https://clinicaltrials.gov/ct2/show/NCT04102436?term=Tcr+Neoantigen+sleeping&rank=1



Go to sections
Brief Summary:
Background:

The administration of autologous tumor infiltrating lymphocytes (TIL) can mediate complete, durable regressions in 20-25% of patients with metastatic melanoma. Recent studies have shown that these TIL predominantly recognize unique mutated neoantigens expressed by the cancer not shared by other melanomas.
Administration of bulk autologous TIL to patients with a variety of other solid cancers, including cancers of the gastrointestinal tract and genitourinary tract, have little if any therapeutic impact.
Recent studies in the Surgery Branch, NCI, have shown that TIL from non-melanoma solid cancers can also contain T-cells reactive against non-shared unique mutated neoantigens expressed in the cancer. The frequency of these T-cells is very low (often < 0.1%) and it is thus difficult to isolate and grow mutation reactive T-cells to levels required for effective therapy.


In several patients with chemo-refractory metastatic epithelial cancers, we were able to grow an enriched population of neoantigen reactive TIL and administration of these cells mediated several partial regressions of metastatic disease and one complete regression of all metastatic breast cancer now lasting more than 3 years.

We have now developed approaches to identify these rare neoantigen reactive T-cells from common non-melanoma cancers, to isolate their T-cell receptors (TCR), and to genetically engineer autologous peripheral blood lymphocytes (PBL) using the Sleeping Beauty system to express these TCRs with high efficiency. The neoantigen TCR gene- modified cells can recognize and destroy the autologous cancer in vitro.

We are now proposing a clinical protocol to treat patients with refractory solid cancers using the adoptive transfer of autologous PBL transposed with genes encoding TCRs that recognize unique mutated neoantigens expressed by the cancer.

Objective:

-To determine the rate of objective response (using RECIST v1.1 criteria) of patients with solid cancers who receive autologous PBL that have been genetically modified with genes encoding TCRs that recognize mutated neoantigens in the autologous cancer using the Sleeping Beauty system.

Eligibility:

Patients who are age greater than or equal to 18 years and less than or equal to 70 years must have:

Measurable solid cancer with at least one lesion that is resectable for TIL generation with minimal morbidity plus at least one other lesion that can be measured that falls into one of four cohorts: (1) gastrointestinal and genitourinary, (2) breast and ovarian, (3) non- small cell lung cancer (NSCLC), and (4) glioblastoma. Metastatic disease is required for Cohorts 1-3 but not for Cohort 4.
Evaluable solid cancer that has recurred following standard chemotherapy or standard erapy OR therapy has been declined
Adequate organ function
No allergies or hypersensitivity to cyclophosphamide, fludarabine, or aldesleukin.
No concurrent major medical illnesses or any form of immunodeficiency
Design:

Patients will undergo resection or biopsy to obtain tumor for generation of autologous TIL cultures. Patients will be entered into four cohorts that include (1) gastrointestinal and genitourinary tract cancers, (2) breast and ovarian cancers, (3) non-small cell lung cancer (NSCLC), and (4) glioblastomas. Exome sequencing and often RNA Seq will be performed to identify the mutations expressed in the patient s cancer. Multiple autologous TIL cultures will be grown and tested for reactivity against mutations from the autologous tumor using assays we have developed that involve the exposure of autologous antigen presenting cells to long peptides containing the mutation or tandem mini genes encoding the mutation.
T-cell cultures with reactivity against mutations will be identified and the individual TCRs that recognize the mutation will be synthesized and used to transfect the TCR into patient s autologous PBL using the Sleeping Beauty system.
Transposed autologous PBL will then be expanded to large numbers using our standard rapid expansion protocol and administered to the patient following a non-myeloablative lymphodepleting regimen.
All patients will receive a non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine. Patients will then receive the infusion of autologous transposed PBL and begin high-dose aldesleukin (720,000 IU/kg IV every 8 hours for up to 10 doses).
Clinical and immunologic response will be evaluated approximately 4-6 weeks after cell infusion and periodically thereafter.
It is anticipated that approximately one patient per month will enroll into the trial for each of the four histologic groups. Thus, accrual of up to 4 x 50=200 total evaluable patients may be completed in approximately 2-4 years. In order to allow for a small number of ineval...

[WalkingHome]

its at the 200 sma so might be a place to bottom. too soon to tell.
I added here, but would recommend wait and see.
several drug treatments in the pipeline.
Adding top talent.
Good signs all around.
of course biotech is out of favor at the moment

[dirtydozen911]

$20 million offering last week, has this pulling back nicely.
might take another bite if she drops under $4.....to $380..390..?? $$$$$$$$$ ZIOP $$$$$$$$$$...someday!

this has been a great swing, have been playing it for years...GLTA

[whytestocks]

News: $ZIOP Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective...

Read the whole news Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

[ClayTrader]

* * $ZIOP Video Chart 08-08-2019 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $ZIOP Ziopharm Oncology to Host Conference Call to Discuss Second Quarter 2019 Results on August 8, 2019

BOSTON, July 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8, at 8:30 a.m. ET to provide a corporate update and discuss financial results for the second quarter ended June 30...

In case you are interested Ziopharm Oncology to Host Conference Call to Discuss Second Quarter 2019 Results on August 8, 2019

[ClayTrader]

* * $ZIOP Video Chart 07-26-2019 * *

Link to Video - click here to watch the technical chart video

[WalkingHome]

huge potential-

[dirtydozen911]

good to see this heading north again.......a few years back, this was a $15 stock.......$$$$$$$$$$$ ZIOPHARM $$$$$$$$$

[Plegee]

That is a significant announcement for ZIOP. Great NIH and MDA connections should give our minimal company some bandwidth as future development and clinical trials start. Plus, like the idea that such a renowned researcher accepts our clinical approach.

[whytestocks]

News: $ZIOP Ziopharm Oncology Names NCI's Dr. Drew Deniger to Direct TCR-T Cell Therapy Program

BOSTON, July 03, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Drew Deniger, Ph.D., will join Ziopharm from the National Cancer Institute (NCI) to lead the company’s program to genetically...

In case you are interested Ziopharm Oncology Names NCI's Dr. Drew Deniger to Direct TCR-T Cell Therapy Program

[jondoeuk]

Why would you think that?

[blackcat]

And this is a problem for you why?

[jondoeuk]

She owns 339 shares!

[ClayTrader]

* * $ZIOP Video Chart 06-17-2019 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $ZIOP Ziopharm Oncology Appoints Heidi Hagen to Board of Directors

BOSTON, June 17, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Heidi Hagen, an experienced and entrepreneurial biotechnology operations executive, has been appointed to the Company’s Board...

In case you are interested https://marketwirenews.com/news-releases/ziopharm-oncology-appoints-heidi-hagen-to-board-of-directors-8368312.html